BRAF基因突变与甲状腺乳头状癌淋巴结转移相关性的研究(2)
 |
| 第1页 |
参见附件。
[2] Anqoulvant D, Clerc A, Benchalal S, et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheoloqy,2004, 41 (324):469-476.
[3] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood,2005, 105 (4): 1815-1822.
[4] Ogawa S, Nitta K, Hara Y, et al. CD 28 knockout mice as a useful clue to exam in the pathogenesis of chronic graft-versus-host reaction. Kidney Int,2000, 58 (5):2215-2220.
[5] Sithanandam G, Druck T. B-raf and a B-raf pseudogene are located on 7qin man. Oncogene, 1992, 7: 795-799.
[6] Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta,2003, 1653:25-40.
[7] Knauf JA, Ma X. Targeted expression of BRAFV600E in thyroid cells of transgenic mice result s in papillary thyroid cancers that transition to undifferentiated carcinomas. The 76th American Thyroid Association Annual meeting, Vancouver, British Columbia, Canada,2004: 45-48.
[8] Kebebew E，Weng J，Bauer J，et al.The prevalence and prognostic value of BRAF mutation in thyroid cancer.Ann Surg，2007，246(3)：466-471.
[9] Xing M，Westra W H，Tufano R P，et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.J Clin Endocfinol Metab，2005,90(12)：6373-6379.
[10] Kim J，Giuliano A E，Turner R R，et al.Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.Ann Surg，2006，244(5)：799-804.
[11] Elisei R，Ugolini C，Viola D，et al.BRAF(V600E)mutation and outcome of patients with papillary thyroid carcinoma：a 15 year median follow-up study.J Clin Endocrinol Metab，2008，93(10)：3943-3949.
(收稿日期：2011-08-23)
(本文编辑：车艳)
您现在查看是摘要介绍页，详见PDF附件。